&w=3840&q=100)
Paytm shares fall 2% after large trade; Here's the likely seller
The company's stock fell as much as 1.87 per cent during the day to ₹1,058 per share, the steepest intraday fall since July 31 this year. The stock pared losses to trade 1.1 per cent lower at ₹1,066 apiece, compared to a 0.40 per cent advance in Nifty 50 as of 10:17 AM.
Shares of the company have been range-bound since the latter part of July and currently trade at 38 times the average 30-day trading volume, according to Bloomberg. The counter has risen 5.1 per cent this year, compared to a 4.3 per cent advance in the benchmark Nifty 50. One 97 Communications has a total market capitalisation of ₹68,354.46 crore. Track LIVE Stock Market Updates Here
One 97 Communications block deal
Paytm shares were the most-traded Indian stock by value and volume, according to Bloomberg, as about 18.7 million shares, or 2.9 per cent equity stake, changed hands on BSE. The buyers and sellers were not known immediately.
Meanwhile, the news agency earlier reported that an affiliate of China's Ant Group Co. is looking to exit Paytm in a deal valued at about $434 million. Antfin Netherlands Holding B.V. has offered to sell as many as 37.3 million shares, it said, at a floor price of ₹1,020 per share. Citigroup Inc., Goldman Sachs Group were managing the sale, it added.
As per shareholding data available on the BSE, Antfin held about 5.84 per cent stake in the company as of the June 2025 quarter. In August 2023, it had offloaded a 10.3 per cent stake in the company. Prior to it, the investor held a 23.79 per cent stake in Paytm as of the June 2023 (Q1FY24) quarter, data from the BSE shows.
Antfin is the last remaining Chinese shareholder, and once the deal is executed, Paytm will no longer have any Chinese ownership.
JM Financial on Antfin exit
If the Chinese investor exits the company, it would remove a long-standing overhang, potentially leading to a positive reaction in Paytm's stock as ownership concerns ease and supply pressure subsides, JM Financial said. "Such clean-out trades often provide clarity to the market, allowing investors to refocus on fundamentals and future growth."
The exit also aligns the cap table more closely with regulatory expectations, which could be viewed favourably in the context of Paytm's pending payment aggregator license, it added.
Paytm shares have rebounded strongly from the January 2024 regulatory setback, reporting PAT profitability in Q1FY26. Higher contribution margins and controlled indirect expenses may drive a sharp rise in profits, with focus shifting back to sustainable growth, the brokerage said.
Paytm Q1 results
The June quarter (Q1FY26) marked a turnaround for Paytm as the company reported a consolidated profit of ₹122.5 crore, against a net loss of ₹838.9 crore in Q1FY25. Paytm had posted a net loss of ₹539.8 crore in Q4FY25.
Additionally, its revenue from operations grew 27.7 per cent to ₹1,917.5 crore in Q1FY26 from ₹1,501.6 crore in Q1FY25. Sequentially, revenue from operations remained stagnant compared to ₹1,911.5 crore in Q4FY25.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Economic Times
2 minutes ago
- Economic Times
Eris Lifesciences eyes ‘good' share in semaglutide generics, says COO
Mr. Krishnakumar Vaidyanathan, Executive Director & Chief Operating Officer Eris Lifesciences looks to leverage its experience in integrated diabetes portfolio to take a lead among the first wave of generic semaglutide anti-diabetic and weight-loss drugs to hit the market early next year, a top official said. The company is looking at a 'good' share of the market, Krishnakumar Vaidyanathan, executive director and chief operating officer of Eris Lifesciences, told ET in an interaction. Semaglutide is the active ingredient in Novo Nordisk's blockbuster drugs Wegovy and Ozempic. Its patent in India will expire in March 2026. 'We are gearing up to be among the first to enter the market post loss of exclusivity,' Vaidyanathan said. 'We expect the overall market for GLP-1 at the end of the first 12 months (after the loss of exclusivity) to be at least 10 million units… And we expect to get a good share of the market.' Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist. Eris Lifesciences' existing diabetes portfolio includes orals, insulin and GLP-1 in the form of liraglutide. Its network of field representatives, patient connect and service platform in this space gives the firm an advantage over others, Vaidyanathan said. 'We do this day in and day out because of insulin. That gives us the confidence that we'll be able to step this up for GLP-1 as well.'Globally, the GLP-1 market is dominated by Eli Lilly and Novo Nordisk, which are also the two biggest insulin companies in the world. 'Being successful and big in the insulin market provides a huge tailwind when it comes to selling GLPs,' Vaidyanathan said. 'We have combined service with technology and product to create a winning combination in insulin and GLP therapy entry is not any different, which also requires a lot of patient education over and above the service on using the pens,' he said. 'We have an integrated diabetes portfolio because we currently sell GLP-1 in the form of liraglutide.' Dr Reddy's Labs, Sun Pharmaceutical Industries, Cipla, Mankind Pharma, Torrent Pharmaceuticals, and Zydus Lifesciences are also among Indian drugmakers readying to launch generic semaglutide next year. Eris Lifesciences launched liraglutide, a once-a-week GLP-1 product, last September. 'We have taken very good market shares in all the other LOE (loss of exclusivity) opportunities that we have seen in diabetes,' Vaidyanathan said. 'We have taken market ranks of 1 to 5 in each one without exception – vildagliptin, sitagliptin, linagliptin, dapagliflozin and empagliflozin. That gives us the confidence that we should be getting a fair share of the market.' Vishal Manchanda, pharma analyst at brokerage Systematix Group, said its full portfolio of anti-diabetes drugs to offer to diabetologist, spanning all oral and injectable options, should give Eris Lifesciences 'a strong positioning in a market where the large pharma majors like Sun, Lupin, Dr Reddy's, Cipla, Mankind and Zydus come in with their dominant brand presence.'
Hans India
5 minutes ago
- Hans India
Vedanta continues winning street confidence: Brokerages forecast strong earnings ahead
New Delhi: Major global and Indian brokerages remain optimistic on Vedanta Ltd's performance for FY26, citing stronger LME pricing trends, cost discipline, deleveraging, and a resilient aluminium business among the key growth drivers. These firms have also taken note of the several growth projects scheduled for commissioning or completion in the next few quarters. JP Morgan noted that Vedanta's first quarter consolidated EBITDA was largely in line with estimates, with key segments such as aluminium, oil and gas, and power faring better than its expectations, leading to an overall segmental EBITDA beat. On the earnings trajectory for the current and next fiscal, the firm expects various ongoing initiatives at Vedanta to aid growth. "Vedanta's capacity expansion journey in the aluminium business as well as vertical integration should bring cost advantages. LME prices have also bottomed out and should continue to move higher into FY26-27, likely aiding earnings growth." Echoing similar views on LME prices and its potential benefit, Citi Research cited that Vedanta's parent (Vedanta Resources) leverage is at comfortable levels. It listed potential upside in medium-term aluminium LME prices, lower cost, and the demerger as another positive for Vedanta, while adding that aluminium globally has a limited supply growth. Mumbai-based Nuvama Institutional Equities expects Vedanta to deliver quarter-on-quarter EBITDA growth in Q2. "Q2FY26 EBITDA is likely to increase 10 per cent-plus quarter-on-quarter on the back of higher prices and lower aluminium cost of production. Major aluminium projects are likely to be commissioned in Q2FY26. We reckon net debt/EBITDA ex-Hindustan Zinc shall fall to 1.7x by FY26-end, compared to 2.7x in FY25. Demerger of the business is likely to be concluded in Q4FY26," the firm said in its report. The brokerage expects Vedanta's all major projects except coal blocks to be likely commissioned in the current fiscal, providing volume growth and cost reduction visibility for the company. UK-based Investec stated in its post-earnings report that Vedanta is a key beneficiary of depreciation in the Indian Rupee. Other near-term positives listed by the firm include declining alumina prices and the company offering attractive yields. The firm has retained its buy recommendation on Vedanta. Research firms like Kotak Institutional Equities and IIFL have cited factors like cost efficiencies and deleveraging at both Vedanta Ltd and its parent Vedanta Resources as beneficial factors. Vedanta's adjusted profit after tax jumped 13 per cent year-on-year to Rs 5,000 crore. The company clocked its highest-ever first-quarter EBITDA of Rs 10,746 crore, which was up 5 per cent year-on-year.
NDTV
5 minutes ago
- NDTV
Trump Says US China Close To Trade Agreement, Will Meet Xi If Deal Is Struck
President Donald Trump said on Tuesday the US was close to a trade deal with China and that he would meet his Chinese counterpart Xi Jinping before the end of the year if an agreement is struck. "He asked for a meeting, and I'll end up having a meeting before the end of the year most likely, if we make a deal. If we don't make a deal, I'm not going to have a meeting," Trump told CNBC in an interview referring to China's Xi. "We're getting very close to a deal. We're getting along with China very well," Trump said. Treasury Secretary Scott Bessent said last week he believed the US had the "makings of a deal" with China after officials from the two countries met in Stockholm in a bid to resolve economic disputes aimed at extending their truce on a trade war by three months. China is facing an August 12 deadline to reach a durable tariff agreement with the US administration, after Beijing and Washington reached preliminary deals in May and June to end escalating tit-for-tat tariffs and a cut-off of rare earth minerals. Without a deal, global supply chains could face renewed turmoil from US duties snapping back to triple-digit levels that would amount to a bilateral trade embargo. Speaking to CNBC, Trump also said his administration would soon impose tariffs on US imports of pharmaceuticals, semiconductors and chips, which is expected to impact China.
